Polymorphism 3435c> t of the ABCB1 gene (rs1045642) does not affect the mirtazapine efficiency and safety profile in patients with depressive disorders comorbid with alcohol use disorder
Background. Mirtazapine is used to treat patients with depressive disorders. A large proportion of patients in this group do not adequately respond to mirtazapine therapy, while many develop undesirable drug reactions of type A. According to the previous studies, P-gp is involved in the biotransform...
Main Authors: | M. S. Zastrozhin, E. A. Grishina, K. A. Ryzhikova, V. Yu. Skryabin, S. G. Koporov, E. A. Bryun, D. A. Sychev |
---|---|
Format: | Article |
Language: | English |
Published: |
Siberian State Medical University (Tomsk)
2021-01-01
|
Series: | Бюллетень сибирской медицины |
Subjects: | |
Online Access: | https://bulletin.ssmu.ru/jour/article/view/4152 |
Similar Items
-
The relationship between the CYP2C19*17 genetic polymorphism and the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome
by: V. Yu. Skryabin, et al.
Published: (2020-01-01) -
Clinical characteristics and efficiency of antidepressant therapy of mood disorders with comorbid alcohol use disorder
by: O. V. Roshchina, et al.
Published: (2021-07-01) -
Клиническая фармакогенетика: тернистый путь внедрения в клиническую практику
Published: (2018-06-01) -
Clinical value of comorbidity of affective disorders and alcohol dependence
by: O. V. Roshchina, et al.
Published: (2020-01-01) -
Фармакогенетические аспекты эффективности терапии клозапином при фармакорезистентной шизофрении
by: Кравцов, В.В., et al.
Published: (2019-09-01)